Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.

Kim DK, Koo KC, Lee KS, Hah YS, Rha KH, Hong SJ, Chung BH.

J Korean Med Sci. 2018 Oct 16;33(45):e285. doi: 10.3346/jkms.2018.33.e285. eCollection 2018 Nov 5.

2.

Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.

Kumar A, Samavedi S, Mouraviev V, Bates AS, Coelho RF, Rocco B, Patel VR.

J Robot Surg. 2017 Mar;11(1):37-45. doi: 10.1007/s11701-016-0606-8. Epub 2016 May 31.

PMID:
27245233
3.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
4.

Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.

Kim DK, Koo KC, Abdel Raheem A, Kim KH, Chung BH, Choi YD, Rha KH.

PLoS One. 2016 Mar 31;11(3):e0152391. doi: 10.1371/journal.pone.0152391. eCollection 2016.

5.

Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.

Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

World J Urol. 2016 Oct;34(10):1357-66. doi: 10.1007/s00345-016-1781-y. Epub 2016 Feb 12.

PMID:
26873596
6.

Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.

Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, Suardi N, Montorsi F, Briganti A, Rocco B, Mottrie A.

Eur Urol. 2017 Feb;71(2):249-256. doi: 10.1016/j.eururo.2016.05.008. Epub 2016 May 18.

PMID:
27209538
7.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
8.

Oncologic outcomes at 10 years following robotic radical prostatectomy.

Diaz M, Peabody JO, Kapoor V, Sammon J, Rogers CG, Stricker H, Lane Z, Gupta N, Bhandari M, Menon M.

Eur Urol. 2015 Jun;67(6):1168-1176. doi: 10.1016/j.eururo.2014.06.025. Epub 2014 Jul 2.

PMID:
24996687
9.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
10.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

11.

Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis.

Wang L, Wang B, Ai Q, Zhang Y, Lv X, Li H, Ma X, Zhang X.

Int Urol Nephrol. 2017 Jun;49(6):995-1005. doi: 10.1007/s11255-017-1552-8. Epub 2017 Feb 25. Review.

PMID:
28238148
12.

Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.

Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G, Wiklund NP.

Eur Urol Focus. 2018 Apr;4(3):351-359. doi: 10.1016/j.euf.2016.10.007. Epub 2016 Nov 2.

PMID:
28753802
13.

Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.

Abdollah F, Klett DE, Sood A, Sammon JD, Pucheril D, Dalela D, Diaz M, Peabody JO, Trinh QD, Menon M.

BJU Int. 2015 Nov;116(5):703-12. doi: 10.1111/bju.12998. Epub 2015 May 11.

14.

Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.

Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P.

Eur Urol. 2012 Nov;62(5):768-74. doi: 10.1016/j.eururo.2012.05.024. Epub 2012 May 18.

PMID:
22633365
15.

Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer.

Lee D, Choi SK, Park J, Shim M, Kim A, Lee S, Song C, Ahn H.

Korean J Urol. 2015 Aug;56(8):572-9. doi: 10.4111/kju.2015.56.8.572. Epub 2015 Jul 29.

16.

Oncological outcomes after robot-assisted radical prostatectomy: long-term follow-up in 4803 patients.

Sukumar S, Rogers CG, Trinh QD, Sammon J, Sood A, Stricker H, Peabody JO, Menon M, Diaz-Insua M.

BJU Int. 2014 Dec;114(6):824-31. doi: 10.1111/bju.12404.

17.

Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study.

Lughezzani G, Lazzeri M, Buffi NM, Abrate A, Mistretta FA, Hurle R, Pasini L, Castaldo L, Zandegiacomo De Zorzi S, Peschechera R, Fiorini G, Taverna G, Casale P, Guazzoni G.

Urol Oncol. 2015 Aug;33(8):337.e7-14. doi: 10.1016/j.urolonc.2015.05.007. Epub 2015 Jun 6.

PMID:
26055430
18.

Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.

GarcĂ­a-Barreras S, Rozet F, Nunes-Silva I, Srougi V, Sanchez-Salas R, Barret E, Galiano M, Cathelineau X.

Clin Transl Oncol. 2018 Aug;20(8):1004-1010. doi: 10.1007/s12094-017-1812-1. Epub 2017 Dec 14.

PMID:
29243074
19.
20.

How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?

Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR.

BJU Int. 2013 Aug;112(4):E314-20. doi: 10.1111/j.1464-410X.2012.11493.x. Epub 2013 Mar 4.

Supplemental Content

Support Center